Endologix (ELGX) Shares are Up 0.47%

Endologix (ELGX) : Traders are bullish on Endologix (ELGX) as it has outperformed the S&P 500 by a wide margin of 5.31% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.31%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.47% in the last 1 week, and is up 4.75% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 1.13% and the 50-Day Moving Average is 1.78%.The 200 Day SMA reached 18.36%


Endologix (NASDAQ:ELGX): After opening at $12.43, the stock dipped to an intraday low of $12.4 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $12.8699 and the buying power remained strong till the end. The stock closed at $12.8 for the day, a gain of 3.31% for the day session. The total traded volume was 591,240. The stocks close on the previous trading day was $12.8.

Endologix (ELGX) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $16 and the lowest price target forecast is $12. The average forecast of all the analysts is $14.81 and the expected standard deviation is $1.51.

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Companys products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The Companys EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.